Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon V Tiu

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Blood|August 11, 2011
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3AAnna M Jankowska, Hideki Makishima, Ramon V Tiu, et al.
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of the National Cancer Institute|March 1, 2014
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiationSudipto Mukherjee, Chandana A Reddy, Jay P Ciezki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 2, 2010
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010Michael A Pulsipher, Neal S Young, Jakub Tolar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Leukemia Research|August 21, 2014
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412Paula de Melo Campos, João A Machado-Neto, Renata Scopim-Ribeiro, et al.
Haematologica|July 10, 2012
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaSarah Abu Kar, Anna Jankowska, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> MutationsYung-Mae M Yao, Gregory P Donoho, Philip W Iversen, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Blood|August 11, 2011
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3AAnna M Jankowska, Hideki Makishima, Ramon V Tiu, et al.
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of the National Cancer Institute|March 1, 2014
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiationSudipto Mukherjee, Chandana A Reddy, Jay P Ciezki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 2, 2010
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010Michael A Pulsipher, Neal S Young, Jakub Tolar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Leukemia Research|August 21, 2014
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412Paula de Melo Campos, João A Machado-Neto, Renata Scopim-Ribeiro, et al.
Haematologica|July 10, 2012
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaSarah Abu Kar, Anna Jankowska, Hideki Makishima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> MutationsYung-Mae M Yao, Gregory P Donoho, Philip W Iversen, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Pageof 9